Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Antipsychotic Treatments

Posted by Matt Breese on Oct 12, 2017

Find me on:

new-blog-image-access-1.png

Atypical antipsychotics, also known as second-generation antipsychotics, are commonly used to treat conditions such as schizophrenia, bipolar disorder, severe cases of dementiaanxiety disorder and autism.

Clinicians today tend to prescribe atypical antipsychotics instead of typical antipsychotics, which are first-generation treatment options. Industry trends also reveal an increasing range of on-label and off-label uses, according to a report published by the National Center for Biotechnology Information.

The American Diabetes Association and American Psychiatric Association have recommended that patients who will be prescribed antipsychotics receive more intensive screening for diabetes and abnormalities in lipids to combat health risks. 

According to a report completed by the University of Colorado Anschutz Medical Campus:

"The biggest gap in screening is among adults age 40 and younger, the group for whom early detection and intervention has been shown to be effective when additional cardiovascular risk is present."


For more key findings on clinical characteristics, antipsychotic drug market access and payer coverage, download MMIT's Reality Check on Antipsychotics by clicking on the button below. 

View Reality Check

Topics: Specialty, Market Access